Novartis AG 2019 Q1 - Results - Earnings Call Slides
Apr. 24, 2019 6:32 AM ET | About: Novartis AG (NVS)
Biogen Inc. 2019 Q1 - Results - Earnings Call Slides
Apr. 24, 2019 7:10 AM ET | About: Biogen Inc. (BIIB)
Thermo Fisher Scientific Inc. 2019 Q1 - Results - Earnings Call Slides
Apr. 24, 2019 9:49 AM ET | About: Thermo Fisher Scientific Inc. (TMO)
Boston Scientific Corporation 2019 Q1 - Results - Earnings Call Slides
Apr. 24, 2019 9:50 AM ET|1 comment | About: Boston Scientific Corporation (BSX)
FARXIGA Study Showed Reduced Progression of Kidney Disease or Renal Death in Patients with Type 2 Diabetes
Mon June 10, 2019 8:00 AM|Business Wire|About: AZN
WILMINGTON, Del.--(BUSINESS WIRE)
Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes
Sun June 9, 2019 7:30 PM|PR Newswire|About: LLYPR Newswire
INDIANAPOLIS, June 9, 2019 /PRNewswire/
BriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston
Tue April 23, 2019 6:30 AM|GlobeNewswire|About: BCTXF, MRK
BERKELEY, Calif. and VANCOUVER, British Columbia, April 23, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (BCTXF) ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF)
Basel, 23 April 2019
Roche launches new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients eligible for targeted therapy
Patients living with Spinal Muscular Atrophy (SMA) in the province of Saskatchewan gain access to SPINRAZA™ (nusinersen)
Mon April 22, 2019 7:00 AM|Canada Newswire|About: BIIB
AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI™ (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis
Tue April 23, 2019 6:19 PM|PR Newswire|About: ABBV
Stryker reports first quarter 2019 operating results
Tue April 23, 2019 4:05 PM|GlobeNewswire|About: SYK
Kalamazoo, Michigan, April 23, 2019 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2019:
First Quarter Highlights
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)
Mon April 22, 2019 6:45 AM|Business Wire|About: MRK
Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week Placebo-Controlled Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
04/22/2019Download PDF
INDIANAPOLIS, April 22, 2019 /PRNewswire/ -- Eli Lilly and Company(NYSE: LLY) announced today that Taltz® (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a Phase 3 study
Medtronic VenaSeal(TM) Closure System Demonstrates Durable and Consistent Outcomes at Five Years in Patients with Chronic Venous Disease
Wed April 17, 2019 5:00 AM|InPublic US|About: MDT
AveXis data reinforce effectiveness of Zolgensma® in treating spinal muscular atrophy (SMA) Type 1
Basel, April 16, 2019 - AveXis, a Novartis company,
Zolgensma, previously knowns as AVXS-101, is the proprietary gene therapy candidate from AveXis designed to treat spinal muscular atrophy (SMA).
Health Canada Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis
Thu April 18, 2019 10:04 AM|Canada Newswire|About: ABBV
MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Familial Adenomatous Polyposis
Mon April 15, 2019 4:25 PM|Accesswire|About: JNJ, MOR
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 15, 2019 / MorphoSys AG (MPSYF) (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR)
Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD
Apr 15, 2019
Basel, April 15, 2019
Data on Impact of Revised Consensus Recommendations on Time to Treatment and Serum Creatinine (SCr) at Treatment Start for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Presented at the 2019 International Liver Congress™ (EASL)
Mon April 15, 2019 6:45 AM|PR Newswire|About: MNKPR Newswire
STAINES-UPON-THAMES, United Kingdom, April 15, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK) (NYSE: MNK)
WuXi Biologics teams up with I-Mab Bio for clinical programs
Apr. 16, 2019 8:23 AM ET|About: Wuxi Biologics (Cayman) In... (WXXWY)|By: Mamta Mayani, SA News Editor
CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia
Tue April 16, 2019 7:00 AM|GlobeNewswire|About: CRSP, VRTX
ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, April 16, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals Incorporated (VRTX)
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK) Results of Phase 3 Trial Evaluating Merck’s ZERBAXA® (ceftolozane and tazobactam) versus Meropenem for Treatment of Adult Patients with Ventilated Nosocomial Pneumonia (VNP) to be Presented at ECCMID 2019
Sat April 13, 2019 7:00 AM|Business Wire|About: MRK
INVOKANA® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Melbourne, Australia, April 14, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson
Phase 3 CREDENCE Study
QIAGEN Launches First FDA-Approved Companion Diagnostic Using FGFR Alterations to Help Guide the Treatment of Metastatic Urothelial Cancer
Fri April 12, 2019 3:23 PM|Business Wire|About: QGEN
Novel therascreen® FGFR RGQ RT-PCR Kit will aid in identifying patients eligible for treatment with BALVERSA™ (erdafitinib), developed by Janssen
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)-- QIAGEN N.V. (QGEN
Bristol-Myers shareholders back Celgene takeover
Apr. 12, 2019 10:54 AM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor
BALVERSA™ (erdafitinib) Receives U.S. FDA Approval for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alterations
Horsham, PA, April, 12 – The Janssen Pharmaceutical Companies of Johnson & Johnson
Gilead Presents New Data on Viral Hepatitis at the International Liver Congress™ 2019
Thu April 11, 2019 9:18 AM|Business Wire|About: GILD
– Data Demonstrate Role of Gilead HCV Medicines in Difficult–to-Treat Patient Populations and in Real-World Settings –
– Latest HBV Data Reinforce Role of Treatment with Vemlidy and Demonstrate Progress in Cure Research –
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD)
AbbVie's MAVIRET™ now reimbursed in Quebec
Thu April 11, 2019 9:00 AM|Canada Newswire|About: ABBV
MONTREAL, April 11, 2019 /CNW/ - AbbVie (ABBV)
Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen in a Rapid Initiation Model of Care Demonstrating Safety and Efficacy with SYMTUZA® through 48 Weeks
High Proportion of Patients Achieve Undetectable Viral Loads after Rapidly Starting SYMTUZA®1
Miami, FL., April 11, 2019
Health Canada issues Notice of Compliance with Conditions (NOC/c) for LibtayoTM (cemiplimab), the first and only biologic for the treatment of advanced cutaneous squamous cell carcinoma (CSCC)
Thu April 11, 2019 2:43 PM|Canada Newswire|About: SNY
Source: Sanofi (SNY) (EURONEXT: SAN) (NYSE: SNY)
* CSCC is the second most common skin cancer in Canadai
TORONTO, April 11, 2019 /CNW Telbec/ - Sanofi Genzyme
Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
Sat April 13, 2019 4:00 AM|Business Wire|About: PFE
Veracyte (VCYT) Presents At 18th Annual Needham Healthcare Conference - Slideshow
Apr. 10, 2019 12:17 PM ET | About: Veracyte, Inc. (VCYT)
Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019Patients Receiving 5 mg Daily Doses of VK2809 Demonstrated Statistically Significant Median Reduction in Liver Fat Content of 53.8%88% of Patients Receiving VK2809 Experienced ≥ 30% Reduction in Liver Fat Content at 12 Weeks, Including all Patients Receiving 5 mg Daily DosesVK2809 was Safe and Well Tolerated at all Doses Studied; No SAEs Reported in Any Cohort
SAN DIEGO, April 11, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX)
Galectin Therapeutics (GALT) Presents At H.C. Wainwright & Co. Annual Global Life Sciences Conference - Slideshow
Apr. 9, 2019 2:19 PM ET | About: Galectin Therapeutics, Inc. (GALT)
Apr 11, 2019
Intercept Reports Additional Positive Data from REGENERATE, the First Successful Phase 3 Study in NASH
OCA significantly improved fibrosis in patients with liver fibrosis due to NASH and demonstrated consistent efficacy across multiple histologic and biochemical parameters
REGENERATE data to be presented during the Opening Ceremony of EASL
NEW YORK, April 11, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT)
Gilead's GS-9674/GS-0976 shows positive action in POC NASH study
Apr. 11, 2019 7:08 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor
BioAtla and BeiGene Form Worldwide Collaboration to Develop and Commercialize Novel Conditionally Active Biologic CTLA-4 Therapy
Tue April 9, 2019 6:05 AM|GlobeNewswire|About: BGNEGlobeNewswire
SAN DIEGO and BEIJING, China and CAMBRIDGE, Mass., April 09, 2019 (GLOBE NEWSWIRE) -- BioAtla ®, LLC
LYNPARZA® (olaparib) Approved in EU for the Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer
Wed April 10, 2019 6:45 AM|Business Wire|About: MRK
AstraZeneca and Merck’s LYNPARZA Reduced the Risk of Disease Progression or Death by 42 Percent Versus Chemotherapy in Phase 3 OlympiAD Trial
First PARP Inhibitor Approved in the EU for This Indication and Third EU Approval for LYNPARZA
KENILWORTH, N.J.--(BUSINESS WIRE)-- AstraZeneca and Merck (MRK)
https://www.lynparzahcp.com/recurrent-ovarian-cancer/olaparib-efficacy/first-line-efficacy.html
Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinson’s Motor Symptoms With Resiniferatoxin (RTX) Intrathecal Administration
Wed April 10, 2019 9:00 AM|GlobeNewswire|About: SRNE
SAN DIEGO, April 10, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (SRNE)
FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
PR Newswire
THOUSAND OAKS, Calif. and BRUSSELS, April 9, 2019 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB THOUSAND OAKS, Calif. and BRUSSELS, April 9, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB)
Geron (GERN) Presents At 18th Annual Needham Healthcare Conference - Slideshow
Apr. 9, 2019 3:49 PM ET|8 comments | About: Geron Corporation (GERN)
Sanofi provides unprecedented access to its insulins for one set monthly price
PR Newswire
BRIDGEWATER, N.J., April 10, 2019 /PRNewswire/ -- Starting in June, Sanofi (SNY)
Regeneron teams up with Alnylam to develop new RNAi therapies
Apr. 8, 2019 7:28 AM ET|About: Alnylam Pharmaceutical... (ALNY)|By: Douglas W. House, SA News Editor
Sarepta Therapeutics’ Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clinical Data has been Accepted for a Late-breaking Oral Presentation at the 2019 MDA Clinical and Scientific Conference
Mon April 8, 2019 8:30 AM|GlobeNewswire|About: SRPTGlobeNewswire
CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (SRPT)
Mon April 8, 2019 7:00 AM|Business Wire|About: TTPH
WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc. (TTPH) (NASDAQ:TTPH)
XERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosus group, Clostridium perfringens, Bacteroides species, and Parabacteroides distasonis in patients 18 years or older.
Immunomedics Announces Promotion Agreement With Janssen for Erdafitinib in the U.S.
Mon April 8, 2019 9:00 AM|GlobeNewswire|About: IMMU
MORRIS PLAINS, N.J., April 08, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (IMMU), (NASDAQ: IMMU)
Veracyte Announces Publication Highlighting Afirma GSC’s Ability to Rule Out Cancer in Challenging Thyroid Nodule Subtype
Mon April 8, 2019 7:30 AM|Business Wire|About: VCYT
RNA whole-transcriptome and machine learning platform enables genomic test to distinguish benign Hürthle cells, reducing potential for unnecessary surgeries
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT)
https://bmcsystbiol.biomedcentral.com/track/pdf/10.1186/s12918-019-0693-z
New Study Finds Targeted Drug Delivery (TDD) is Associated with a Reduction in Health Care Utilization and Cost for Cancer Pain Patients
Mon April 8, 2019 8:00 AM|InPublic US|About: MDT
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA
Fri April 5, 2019 9:28 AM|Business Wire|About: CELG, XLRN
BLA submission includes both myelodysplastic syndromes and beta-thalassemia indications
EMA marketing application for both indications planned for Q2:19
SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN)
Intercept to Present Results from the First Successful Phase 3 Trial in Patients with Liver Fibrosis Due to NASH at the International Liver Congress™ 2019
Thu April 4, 2019 7:00 AM|GlobeNewswire|About: ICPTGlobeNewswire
NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (ICPT)
Gilead files U.S. application HIV prevention claim for Descovy
Apr. 5, 2019 8:47 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor
PE firms eyeing Perrigo pharma business
Apr. 4, 2019 12:27 PM ET|About: Aclaris Therapeutics, ... (ACRS)|By: Douglas W. House, SA News Editor
Amgen Presents New Data At WCO-IOF-ESCEO 2019 Revealing Osteoporosis Treatment Gap In Europe
Sun April 7, 2019 5:00 AM|PR Newswire|About: AMGNPR Newswire
THOUSAND OAKS, Calif., April 7, 2019 /PRNewswire/ -- Amgen (AMGN)
http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-newsArticle&ID=2393722
U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
Thu April 4, 2019 2:57 PM|Business Wire|About: PFE
Approval of expanded indication based predominately on real-world data
NEW YORK--(BUSINESS WIRE)-- Pfizer (PFE)
https://www.businesswire.com/news/home/20190404005732/en/
Myriad expands partnership with AstraZeneca and Merck
Apr. 4, 2019 8:27 AM ET|About: Myriad Genetics, Inc. (MYGN)|By: Mamta Mayani, SA News Editor
https://www.lynparzahcp.com/recurrent-ovarian-cancer/parp-inhibitor-ovarian-cancer.html
Leading cancer center to evaluate SELLAS' galinpepimut-S in mesothelioma
Apr. 4, 2019 10:07 AM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor
AbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET™
Thu April 4, 2019 10:00 AM|Canada Newswire|About: ABBV
Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019
Thu April 4, 2019 7:30 AM|PR Newswire|About: VKTXPR Newswire
SAN DIEGO, April 4, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. (VKTX)
Endo to supply generic version of PROVENTIL in U.S.
Apr. 5, 2019 7:48 AM ET|About: Endo International plc (ENDP)|By: Mamta Mayani, SA News Editor
Copyright © 2018 seeking biotech alpha - All Rights Reserved. City Photos from Pixabay
Powered by GoDaddy Website Builder